Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
22.64
+0.57 (2.56%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC.
The company is headquartered in New York, New York.
Neurogene Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Rachel McMinn |
Contact Details
Address: 535 W 24th Street, 5th Floor New York, New York 10011 United States | |
| Phone | 855 508 3568 |
| Website | neurogene.com |
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| CUSIP Number | 64135M105 |
| ISIN Number | US64135M1053 |
| Employer ID | 98-0542593 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair and Chief Executive Officer |
| Christine Mikail Cvijic J.D. | President, Chief Financial Officer and Corporate Secretary |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Arvind Sreedharan | Senior Vice President of Business Operations |
| Donna M. Cochener-Metcalfe J.D. | Senior Vice President and General Counsel |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical and Translational Research |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance and Quality Control |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 424B3 | Prospectus |
| Dec 16, 2024 | EFFECT | Notice of Effectiveness |
| Dec 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 2, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 27, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 10-Q | Quarterly Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |